This cohort study evaluated clinical and metabolomic factors predicting regression from impaired fasting glucose (IFG) to normoglycemia among 491 Mexican adults at intermediate cardiometabolic risk over a 2.5-year period. Key findings showed 22.6% reverted to normal glucose levels, with younger age, lower BMI, and lower fasting glucose significantly predicting regression.
